Over the past 2 decades, advances in immunology, imaging, and experimental therapeutics have led to dramatic progress in understanding and treating multiple sclerosis (MS). Currently, there are more than 12 US Food and Drug Administration–approved therapies for MS, with more in development. Magnetic resonance imaging has been shown to be useful both in screening novel anti-inflammatory therapies in phase 2 trials and in identifying patients with suboptimal treatment response in clinical practice. Pharmacologic and other treatment approaches have demonstrated effectiveness in alleviating symptoms and compensating for disability. Despite these advances, there remain many critical needs in understanding and treating MS.
Fox RJ, Rudick RA. The Future of Research in Multiple Sclerosis. JAMA Neurol. 2015;72(8):853-854. doi:10.1001/jamaneurol.2015.0270